BR112019002734A2 - tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart - Google Patents

tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart

Info

Publication number
BR112019002734A2
BR112019002734A2 BR112019002734-3A BR112019002734A BR112019002734A2 BR 112019002734 A2 BR112019002734 A2 BR 112019002734A2 BR 112019002734 A BR112019002734 A BR 112019002734A BR 112019002734 A2 BR112019002734 A2 BR 112019002734A2
Authority
BR
Brazil
Prior art keywords
treatment
hiv infection
antibodies
haart
sustained virological
Prior art date
Application number
BR112019002734-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Yi Wang Chang
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of BR112019002734A2 publication Critical patent/BR112019002734A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112019002734-3A 2016-08-13 2017-08-13 tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart BR112019002734A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662374752P 2016-08-13 2016-08-13
US62/374,752 2016-08-13
PCT/US2017/046668 WO2018035001A1 (en) 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Publications (1)

Publication Number Publication Date
BR112019002734A2 true BR112019002734A2 (pt) 2019-05-14

Family

ID=61197201

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002734-3A BR112019002734A2 (pt) 2016-08-13 2017-08-13 tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart

Country Status (14)

Country Link
US (1) US11292839B2 (cg-RX-API-DMAC7.html)
EP (1) EP3497133A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019534891A (cg-RX-API-DMAC7.html)
KR (1) KR20190071677A (cg-RX-API-DMAC7.html)
CN (1) CN109996815A (cg-RX-API-DMAC7.html)
AU (1) AU2017312887A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019002734A2 (cg-RX-API-DMAC7.html)
CA (1) CA3033728A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019001814A (cg-RX-API-DMAC7.html)
RU (1) RU2019106804A (cg-RX-API-DMAC7.html)
SG (2) SG11201901203PA (cg-RX-API-DMAC7.html)
TW (1) TW201808998A (cg-RX-API-DMAC7.html)
WO (1) WO2018035001A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201901374B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017312887A1 (en) * 2016-08-13 2019-03-07 United BioPharma, Inc. Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
US12384830B2 (en) 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
CN113840912A (zh) * 2019-05-16 2021-12-24 南京传奇生物科技有限公司 包含识别分子的工程化免疫细胞
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4590688A1 (en) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381295A (en) 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
DE3828582A1 (de) 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
JPH0725794B2 (ja) 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
DE69126301T2 (de) 1990-11-27 1998-01-02 Biogen, Inc., Cambridge, Mass. Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
JPH06125783A (ja) 1991-12-28 1994-05-10 Chemo Sero Therapeut Res Inst 組換え抗hiv抗体およびその調製方法
EP0746613B1 (en) 1994-03-08 2006-05-24 Memorial Sloan-Kettering Cancer Center Recombinant humanized anti-fb5 antibodies
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
JP3231262B2 (ja) 1996-06-05 2001-11-19 株式会社ビー・エム・エル ヒトTh1特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
US5962319A (en) 1997-05-19 1999-10-05 Bml, Inc. Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
JPH10155489A (ja) 1996-11-27 1998-06-16 Asahi Chem Ind Co Ltd 組換え抗体及びそれをコードする核酸
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU3733499A (en) 1998-05-25 1999-12-13 Asahi Kasei Kogyo Kabushiki Kaisha Cell separation device and separation method
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
AU3714800A (en) 1999-03-02 2000-09-21 Schering Corporation Hiv therapy
DK1454137T3 (da) 2001-12-11 2008-06-16 Biotectid Gmbh Anvendelse af en mærket ligand med specificitet for det humane CD4-molekyle
JP2003327536A (ja) 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US20030211470A1 (en) 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
JP5020941B2 (ja) 2005-05-02 2012-09-05 マイメティクス コーポレーション Hivに対して中和活性を有するがil2には中和活性を有さない抗体又はその断片
RU2393873C2 (ru) 2005-05-02 2010-07-10 Майметикс Корпорейшн Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2
US20090214569A1 (en) 2005-08-25 2009-08-27 Government Of The Us, As Represented By The Secretary, Dept. Of Health & Human Services Use of HIV envelope/CD4 complexes for the generation antibodies
WO2007094983A2 (en) 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
WO2014039840A1 (en) 2012-09-07 2014-03-13 Baylor Research Institute Hiv vaccine compositions and methods
CA2906566C (en) 2013-03-14 2024-09-10 Macrogenics, Inc. Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
EP3003355A1 (en) * 2013-05-24 2016-04-13 Cooper Human Systems LLC Methods and compositions for treatment of hiv infection
US11180555B2 (en) * 2014-09-16 2021-11-23 Ubi Us Holdings, Llc. Antibodies directed against CD4 for the treatment and functional cure of HIV
AU2017312887A1 (en) * 2016-08-13 2019-03-07 United BioPharma, Inc. Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Also Published As

Publication number Publication date
ZA201901374B (en) 2022-04-28
SG11201901203PA (en) 2019-03-28
RU2019106804A (ru) 2020-09-21
WO2018035001A1 (en) 2018-02-22
SG10202100268RA (en) 2021-02-25
JP2019534891A (ja) 2019-12-05
KR20190071677A (ko) 2019-06-24
MX2019001814A (es) 2019-07-08
CN109996815A (zh) 2019-07-09
US11292839B2 (en) 2022-04-05
TW201808998A (zh) 2018-03-16
US20190194326A1 (en) 2019-06-27
RU2019106804A3 (cg-RX-API-DMAC7.html) 2021-03-29
CA3033728A1 (en) 2018-02-22
EP3497133A1 (en) 2019-06-19
AU2017312887A1 (en) 2019-03-07
EP3497133A4 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2022015257A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
MY209319A (en) Compounds useful to treat influenza virus infections
MX386782B (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
MX391812B (es) Agonista fxr derivado de esteroides.
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
IN2013MU01749A (cg-RX-API-DMAC7.html)
JOP20180026A1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
BR112017003705A2 (pt) compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
BR112017006005A2 (pt) composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
BR112019027387A8 (pt) Composições imunogênicas
BR112017005134A2 (pt) tratamento e cura funcional de infecção por hiv por anticorpos monoclonais para inibição de entrada de hiv competitiva mediada por cd
MX364704B (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
BR112017009501A2 (pt) método para tratar uma infecção por hcv, método para curar uma infecção por hcv, e, composição farmacêutica.
BR112017003252A2 (pt) terapia com anticorpos contra hiv como substituto de tratamento

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]